Drugs / LGH447
LGH447
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02370706 | May 2015 → Nov 2020 | myelofibrosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02160951 | Sep 2014 → May 2016 | plasma cell myeloma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02144038 | Jul 2014 → Oct 2015 | refractory plasma cell neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02078609 | Mar 2014 → Apr 2019 | acute myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01456689 | Apr 2012 → Jun 2019 | plasma cell myeloma | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LGH447 | “PIM447, formerly LGH447” NCT02370706 ↗ |
| Known as | CPD 8 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3651966 ↗ |
| Known as | NVP-LGH477 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3651966 ↗ |
| Known as | PIM KINASE INHIBITOR LGH447 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3651966 ↗ |
| Known as | PIM447 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02370706 ↗ |
| Action | Inhibit | “pan-PIM inhibitor” NCT02144038 ↗ |
| Modality | Small molecule | — CHEMBL3651966 ↗ |
| Route | Oral | “when administered orally once daily” NCT01456689 ↗ |